周剂量紫杉醇对不宜手术的局部晚期食管癌患者放疗增敏作用及对患者毒副反应发生情况的分析  

Effect of Weekly Dose Paclitaxel on Radiosensitization and Side Effects on Patients with Locally Advanced Esophageal Carcinoma and not Suitable for Surgery

作　　者：齐书然 QI Shu-ran(Department of Radiotherapy,Nanyang Central Hospital,Nanyang Zhengzhou 473000,China)

机构地区：[1]南阳市中心医院放疗科,郑州南阳473000

出　　处：《药品评价》2018年第23期30-32,32,共4页Drug Evaluation

摘　　要：目的:研究分析对不宜手术的局部晚期食管癌患者采用周剂量紫杉醇治疗的放射增敏作用以及毒副反应发生情况。方法:选取2014年03月至2016年03月我院接受的不适宜手术治疗的74例局部晚期食管癌患者为本次研究对象,通过采用抛硬币法随机分组原则,分为研究组和参照组,其中参照组为37例,采用常规放射治疗,研究组为37例,予以放射治疗联合周剂量紫杉醇治疗,比较两组临床治疗效果、毒副反应发生情况以及跟踪随访2年后的生存率、控制率、卡氏评分。结果:比较分析,研究组总有效率为(97.30%),高于参照组总有效率(81.08%),差异具有统计学意义(P<0.05);研究组毒副反应发生率为(21.62%),要稍微高于参照组毒副反应发生率(16.22%),但是两组比较无差异,不具有统计学意义(P>0.05);跟踪随访1年以及2年后,研究组生存率为(95.49%)、(96.42%),控制率为(97.30%)、(81.08%),均高于参照组生存率(75.68%)、(56.76%),控制率(72.97%)、(59.46%),差异具有统计学意义(P<0.05);研究组跟踪随访1年、2年后,其卡氏评分均高于参照组,差异具有统计学意义(P<0.05)。结论:对不宜采用手术治疗的局部晚期食管癌患者实施周剂量紫杉醇治疗,具有十分显著的应用价值,值得临床推广。Objective To study the radiosensitization and toxicity of weekly dose paclitaxel on patients with locally advanced esophageal carcinoma and not suitable for surgery. Methods： From March 2014 to March 2016, 74 patients with locally advanced esophageal cancer who were unsuitable for surgical treatment in our hospital were selected as the study subjects. The patients were randomly divided into study group and reference group by coin toss method. 37 cases in the reference group were treated with conventional radiotherapy and 37 cases in the study group were treated with radiotherapy combined with weekly dose paclitaxel. The survival rate, control rate and Carr score were evaluated after 2 years follow-up. Results： The total effective rate of the study group was 97.30%, which was higher than that of the control group （81.08%, P〈0.05）. The incidence of side effects in the study group was 21.62%, which was slightly higher than that in the reference group （16.22%）, but there was no signicant difference between the two groups （P〉0.05）. The survival rate of the study group was 95.49%, 96.42% and the control rate was 97.30% and 81.08% after 1 and 2 years follow-up, which were higher than the reference group survival rate （75.68%）, （56.76%） , control rate （72.97%）, （59.46%） , the difference was statistically signicant （P〈0.05）. Conclusion ： After 1 year and 2 years follow-up , the scores of the patients with advanced esophageal carcinoma were signicantly higher than those in the reference group （P〈0.05） . Conclusion： The weekly dose paclitaxel therapy should be applied to patients with advanced esophageal cancer which cannot be treated surgically. It has a very signicant application value and worthy of clinical popularization .

关 键 词：紫杉醇 周剂量 局部晚期食管癌 不宜手术 放疗 增敏作用 毒副反应 临床效果 

分 类 号：R979.1[医药卫生—药品]